MGI PHARMA PUBLISHES DATA ON DACOGEN TRIAL

A A

MGI Pharma has published data from a randomized, controlled Phase III trial of Dacogen for injection, a treatment for myelodysplastic syndromes, in the journal Cancer.

The company conducted the randomized, controlled trial of Dacogen versus supportive care in 170 patients with myelodysplastic syndromes meeting French-American-British subtypes and IPSS intermediate-1, intermediate-2, and high-risk prognostic scores.